Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II
Randomized Controlled Trial
[키워드] 1:1
acute phase reactant
Adverse
adverse effect
adverse event
Allogeneic
analyzed
C-reactive protein
caused
CD4
CD8
chest imaging
clinical symptom
clinical trial
control group
COVID-19
Cytokine storm
D-dimer
declined
demonstrated
double-blind
downregulation
duration of hospitalization
Efficacy
Enrollment
evaluate
events
ferritin
FIVE
GMP
hospitalized patient
hypoxia
immune
immune system
increase in
inflammatory lung disease
injection
intravenous infusion
Intubated
Laboratory parameters
lymphocyte
Lymphocyte count
lymphopenia
mechanism
menstrual blood
Menstrual blood stromal cells
Mesenchymal stromal cell
modulate
MSCs
New treatment
outcomes
Oxygen level
Patient
patients
Phase I
Placebo
placebo-controlled clinical trial
pulmonary involvement
Randomized
reduction
Registered
Result
Safety
safety endpoint
SARS-CoV-2
Secretome
severe COVID-19
Significant
significantly
stromal cell
suppress
survival rate
survivor
therapy
treat
treated
Treatment
treatment group
Volume
[DOI] 10.1186/s13287-022-02771-w PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1186/s13287-022-02771-w PMC 바로가기 [Article Type] Randomized Controlled Trial